Pharming Group N.V.
PHAR
$11.72
-$0.63-5.10%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 06/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 22.44% | 22.44% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 22.44% | 22.44% |
| Cost of Revenue | -- | -- | -- | 14.31% | 14.31% |
| Gross Profit | -- | -- | -- | 23.49% | 23.49% |
| SG&A Expenses | -- | -- | -- | 6.40% | 9.45% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -116.43% | -116.43% |
| Total Operating Expenses | -- | -- | -- | 3.16% | 5.68% |
| Operating Income | -- | -- | -- | 159.86% | 136.09% |
| Income Before Tax | -- | -- | -- | 122.61% | 122.61% |
| Income Tax Expenses | -- | -- | -- | 675.90% | 675.90% |
| Earnings from Continuing Operations | -- | -- | -- | 36.11% | 36.11% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -- | -- | -- | 38.46% | 38.46% |
| EBIT | -- | -- | -- | 159.86% | 136.09% |
| EBITDA | -- | -- | -- | 345.83% | 292.00% |
| EPS Basic | -- | -- | -- | 34.80% | 34.80% |
| Normalized Basic EPS | -- | -- | -- | 133.92% | 92.40% |
| EPS Diluted | -- | -- | -- | 29.90% | 29.90% |
| Normalized Diluted EPS | -- | -- | -- | 133.92% | 92.40% |
| Average Basic Shares Outstanding | -- | -- | -- | -3.67% | -3.67% |
| Average Diluted Shares Outstanding | -- | -- | -- | -3.67% | -3.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |